EGFR and non-small cell lung carcinoma: Recent years have seen a paradigm shift in the treatment of advanced NSCLC due to the identification of somatic sensitizing epidermal growth factor receptor (EGFR) gene mutations, such as exon 19 deletion (Ex19del) or exon 21 (L858R) substitution, as targets for tyrosine kinase inhibitors (TKIs).